Alberto Puccini, Medical Oncologist at IRCCS Humanitas Research Hospital, shared on LinkedIn:
“Our PROSIT study is now published in Translational Oncology!
Using whole-transcriptome sequencing on high-risk stage II colon cancer from the phase III TOSCA trial, we identified an Immune Exclusion phenotype: low immune activation and high TGF-β signaling.
It was linked to shorter disease-free survival, independently of MSI status and sidedness. A compact 7-gene signature captured the same biology.
The results are exploratory and need validation. Still, after a very long project, I’m really happy with these promising results.
Huge thanks to Lorenzo Ferrando, Luca Mazzarella and of course Prof. Alberto Sobrero, plus all co-authors, the TOSCA investigators and the patients.”
Title: The impact of PROgnostic SIgnatures in stage II colon cancer patients enrolled in the phase III clinical trial TOSCA: the PROSIT study
Authors: Alberto Puccini, Lorenzo Ferrando, Gianmaria Frige, Eliana Rulli, Ennio Nano, Francesca Bergamo, Alessandro Pastorino, Valentino Martelli, Annamaria Pessino, Anna Garuti, Davide Bedognetti, Alberto Ballestrero, Roberto Labianca, Evaristo Maiello, Nicla La Verde, Ilaria Bernardini, Domenico Cristiano Corsi, Alberto Zaniboni, Giuseppe Aprile, Filippo Pietrantonio, Valter Torri, Matteo Fassan, Sara Lonardi, Gabriele Zoppoli, Luca Mazzarella, Alberto F. Sobrero
Interesting article about colon cancer:
UNICORN Challenges Immunotherapy Resistance in MSS Colon Cancer
